Alnylam Pharmace. buy StockNews.com
Start price
21.02.24
/
50%
€138.00
Target price
21.02.25
-
Performance (%)
75.07%
End price
22.02.25
€241.60
Summary
This prediction ended on 22.02.25 with a price of €241.60. With a performance of 75.07% the BUY prediction by StockNews_com was a big success. StockNews_com has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -0.982% | -0.982% | -10.074% |
| iShares Core DAX® | 1.352% | 0.930% | 6.806% |
| iShares Nasdaq 100 | 3.277% | 4.990% | 41.197% |
| iShares Nikkei 225® | 7.434% | 16.599% | 70.505% |
| iShares S&P 500 | 1.702% | 2.244% | 27.281% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten